Analyze Diet

New therapeutic approaches for equine protozoal myeloencephalitis: pharmacokinetics of diclazuril sodium salts in horses.

Abstract: Diclazuril is a triazine-based antiprotozoal agent which may have clinical application in the treatment of equine protozoal myeloencephalomyelitis (EPM). In this study, the use of the sodium salt diclazuril to increase the apparent bioavailability of diclazuril for the treatment and prophylaxis of EPM and various other Apicomplexan mediated diseases is described. In this study, diclazuril sodium salt was synthesized and administered to horses as diclazuril sodium salt formulations. The absorption, distribution, and clearance of diclazuril sodium salt in the horse are described. Diclazuril was rapidly absorbed, with peak plasma concentrations occurring at 8-24 hours following an oral mucosal administration of diclazuril sodium salt. The mean oral bioavailability of diclazuril as Clinacox was 9.5% relative to oral mucosal administration of diclazuril sodium salt. Additionally, diclazuril in DMSO administered orally was 50% less bioavailable than diclazuril sodium salt following an oral mucosal administration. It was also shown that diclazuril sodium salt has the potential to be used as a feed additive for the treatment and prophylaxis of EPM and various other Apicomplexan mediated diseases.
Publication Date: 2006-04-07 PubMed ID: 16598684
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article
  • Randomized Controlled Trial
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research focuses on the application of diclazuril sodium salt in treating equine protozoal myeloencephalomyelitis (EPM), a disease affecting horses. The study reveals enhanced bioavailability of diclazuril when used in its sodium salt form, providing potential avenues for its application in treatment and disease prevention.

Study Overview

  • The research is centered on diclazuril, a triazine-based antiprotozoal agent, and its sodium salt form.
  • The main aim of the study is to understand whether converting diclazuril into its sodium salt form can enhance its bioavailability for treatment of EPM and various other Apicomplexan mediated diseases.
  • The study involved administering diclazuril sodium salt to horses and assessing its absorption, distribution, and clearance levels.

Results and Findings

  • In the study, diclazuril sodium salt was seen to be rapidly absorbed by the horses, with peak plasma concentrations noted within 8-24 hours following oral mucosal administration of the compound.
  • The bioavailability of diclazuril when used as Clinacox was found to be 9.5% relative to its sodium salt form, indicating that the salt form was better absorbed by the body.
  • Additionally, Diclazuril in DMSO administered orally was seen to be 50% less bioavailable than the sodium salt form, again highlighting the latter’s enhanced absorption capabilities by the body.
  • These findings suggest that diclazuril sodium salt has a potential usage as a feed additive for treating and preventing EPM and other similar diseases mediated by Apicomplexan parasites.

Potential Implications

  • The results of the study could be a significant breakthrough in the treatment and prophylaxis of EPM and similar diseases.
  • With its potential use as a feed additive, the treatment of these diseases could be made easier and more efficient, as it would not necessarily require direct administration to affected horses, thereby reducing possible stress or harm caused by other means of treatment administration.
  • If applied more widely, this research could also provide valuable insights into how the sodium salt forms of other drugs could improve their efficiency. This could potentially pave the way for more effective treatments for various diseases or ailments in horses and other animals.

Cite This Article

APA
Dirikolu L, Karpiesiuk W, Lehner AF, Hughes C, Woods WE, Harkins JD, Boyles J, Atkinson A, Granstrom DE, Tobin T. (2006). New therapeutic approaches for equine protozoal myeloencephalitis: pharmacokinetics of diclazuril sodium salts in horses. Vet Ther, 7(1), 52-72.

Publication

ISSN: 1528-3593
NlmUniqueID: 100936368
Country: United States
Language: English
Volume: 7
Issue: 1
Pages: 52-72

Researcher Affiliations

Dirikolu, Levent
  • Department of Veterinary Science, The Maxwell H. Gluck Equine Research Center, University of Kentucky, Lexington, KY 40546, USA.
Karpiesiuk, Wojciech
    Lehner, Andreas F
      Hughes, Charlie
        Woods, William E
          Harkins, John D
            Boyles, Jeff
              Atkinson, Alfonza
                Granstrom, David E
                  Tobin, Thomas

                    MeSH Terms

                    • Administration, Oral
                    • Animals
                    • Biological Availability
                    • Central Nervous System Protozoal Infections / drug therapy
                    • Central Nervous System Protozoal Infections / veterinary
                    • Chemistry, Pharmaceutical
                    • Coccidiostats / administration & dosage
                    • Coccidiostats / pharmacokinetics
                    • Coccidiostats / therapeutic use
                    • Dimethyl Sulfoxide
                    • Female
                    • Horse Diseases / drug therapy
                    • Horses / blood
                    • Horses / metabolism
                    • Nitriles / administration & dosage
                    • Nitriles / pharmacokinetics
                    • Nitriles / therapeutic use
                    • Salts
                    • Sodium
                    • Triazines / administration & dosage
                    • Triazines / pharmacokinetics
                    • Triazines / therapeutic use

                    Citations

                    This article has been cited 5 times.
                    1. Onzere CK, Hulbert M, Sears KP, Williams LBA, Fry LM. Tulathromycin and Diclazuril Lack Efficacy against Theileria haneyi, but Tulathromycin Is Not Associated with Adverse Clinical Effects in Six Treated Adult Horses.. Pathogens 2023 Mar 14;12(3).
                      doi: 10.3390/pathogens12030453pubmed: 36986375google scholar: lookup
                    2. Bowden GD, Land KM, O'Connor RM, Fritz HM. High-throughput screen of drug repurposing library identifies inhibitors of Sarcocystis neurona growth.. Int J Parasitol Drugs Drug Resist 2018 Apr;8(1):137-144.
                      doi: 10.1016/j.ijpddr.2018.02.002pubmed: 29547840google scholar: lookup
                    3. Van Voorhis WC, Doggett JS, Parsons M, Hulverson MA, Choi R, Arnold SLM, Riggs MW, Hemphill A, Howe DK, Mealey RH, Lau AOT, Merritt EA, Maly DJ, Fan E, Ojo KK. Extended-spectrum antiprotozoal bumped kinase inhibitors: A review.. Exp Parasitol 2017 Sep;180:71-83.
                      doi: 10.1016/j.exppara.2017.01.001pubmed: 28065755google scholar: lookup
                    4. Ojo KK, Dangoudoubiyam S, Verma SK, Scheele S, DeRocher AE, Yeargan M, Choi R, Smith TR, Rivas KL, Hulverson MA, Barrett LK, Fan E, Maly DJ, Parsons M, Dubey JP, Howe DK, Van Voorhis WC. Selective inhibition of Sarcocystis neurona calcium-dependent protein kinase 1 for equine protozoal myeloencephalitis therapy.. Int J Parasitol 2016 Dec;46(13-14):871-880.
                      doi: 10.1016/j.ijpara.2016.08.003pubmed: 27729271google scholar: lookup
                    5. Dubey JP, Howe DK, Furr M, Saville WJ, Marsh AE, Reed SM, Grigg ME. An update on Sarcocystis neurona infections in animals and equine protozoal myeloencephalitis (EPM).. Vet Parasitol 2015 Apr 15;209(1-2):1-42.
                      doi: 10.1016/j.vetpar.2015.01.026pubmed: 25737052google scholar: lookup